US Patent 7,563,871: Claim Scope, Exenatide Formulation Coverage, Expiration and Patent Landscape

US Patent 7,563,871 covers low-porosity biodegradable polymer compositions for sustained release of biologically active polypeptides, with particular protection for once-weekly exendin-4 formulations. The commercial relevance is concentrated in claims 15, 16 and 18-20, which target exendin-4 dispersed in 50:50 poly(lactide-co-glycolide), or PLG, with sucrose and a controlled pore-volume and pharmacokinetic profile.

The patent is associated with the development of extended-release exenatide products such as Bydureon. Its central technical concept is a PLG microsphere formulation engineered to reduce burst release and maintain a Cmax-to-Cave ratio of approximately 3 or less over about one week [1], [2].

The patent’s nominal term was tied to priority filings in the early 2000s. The original composition claims therefore do not represent a long-term current barrier to generic or follow-on development. Commercial risk now depends more heavily on later formulation, manufacturing, device and regulatory patents than on US 7,563,871 itself.

What does US Patent 7,563,871 protect?

The patent protects a sustained-release composition containing three required functional elements:

A biocompatible biodegradable polymer.
A biologically active polypeptide.
A sugar.

The formulation must also satisfy two measurable performance limitations:

Total pore volume of about 0.1 mL/g or less, measured by mercury intrusion porosimetry.
A serum concentration profile with a Cmax/Cave ratio of about 3 or less during the release period.

The principal claim is therefore not limited only by chemical composition. It combines composition limitations with physical characterization and in vivo pharmacokinetic performance.

Core claim architecture

Claim group	Main subject matter	Practical scope
Claim 1	Polymer, polypeptide and sugar; pore volume and Cmax/Cave limitations	Broadest composition claim
Claims 2-4	Polypeptide narrowed to glucoregulatory peptides, GLP-1, GLP-2 and exendins	Peptide-specific scope
Claims 5-10	Peptide and sugar concentration ranges; sucrose and mannitol	Formulation-composition scope
Claims 11-14	Polymer narrowed to PLG, especially 50:50 PLG with 0.3-0.5 dL/g inherent viscosity	Polymer and grade limitations
Claim 15	Exendin-4 at least about 5% w/w and sucrose at least about 2% w/w	Independent exenatide formulation claim
Claim 16	Purified 50:50 DL PLG 4A, exendin-4, sucrose, no ammonium sulfate, human diabetes treatment	Narrowest commercially focused independent claim
Claims 17-20	Approximately one-week release, with exendin-4 in specified embodiments	Once-weekly formulation coverage

How broad is claim 1?

Claim 1 is broad in the identity of the polypeptide and polymer but narrow in its required performance characteristics.

The polypeptide can be selected from a large group that includes hormones, cytokines, antibodies, growth factors, enzymes, interferons, erythropoietin, insulin and exendins. The polymer can be a biodegradable polyester, polyanhydride, polyorthoester, polycaprolactone, polycarbonate or related copolymer.

The practical claim boundary is created by the combination of:

A sugar-containing polymer matrix.
A total pore volume of approximately 0.1 mL/g or less.
A Cmax/Cave ratio of approximately 3 or less.

A formulation containing the listed ingredients would not necessarily infringe claim 1 if it had a higher pore volume or a Cmax/Cave ratio above the claimed level. Conversely, a formulation using a different peptide could fall within claim 1 if all other limitations were met.

Meaning of “consisting essentially of”

Claim 1 uses “consisting essentially of.” This transitional phrase generally permits components that do not materially affect the basic and novel characteristics of the claimed formulation. The basic characteristics appear to be the low-porosity polymer matrix, sustained peptide release and reduced peak-to-average exposure.

The phrase creates a middle position between:

“Comprising,” which generally permits additional components; and
“Consisting of,” which excludes additional components.

Excipients, stabilizers, buffers or processing residues could be evaluated under the materially-affecting standard. An added component that changes pore structure, peptide release or pharmacokinetics could create a claim-construction and infringement issue.

What formulations are protected for exendin-4?

Claims 4-20 progressively concentrate protection on exendin-4 and related glucoregulatory peptides.

Exendin-4 concentration

Claims 5 and 6 require the peptide to be present at:

About 0.1% to about 10% w/w under claim 5.
About 0.5% to about 5% w/w under claim 6.

Claim 15 moves to a separate independent formulation requiring exendin-4 at about 5% w/w or more. The overlap between claim 6 and claim 15 is limited because claim 15 adds a higher minimum concentration and specifies sucrose at about 2% w/w or more.

Sugar concentration and identity

Claims 7 and 8 establish sugar ranges of:

About 0.01% to about 10% w/w.
About 0.1% to about 5% w/w.

Claim 9 includes monosaccharides, disaccharides and sugar alcohols. Claim 10 narrows the sugar to sucrose, mannitol or a combination.

Claim 15 independently requires sucrose at about 2% w/w or more. This is commercially important because it avoids reliance on the broader sugar genus in claim 1.

Polymer limitations

Claims 11-14 cover biodegradable polymers and then narrow to:

Poly(lactide-co-glycolide), or PLG.
50:50 PLG.
Inherent viscosity of approximately 0.3 to 0.5 dL/g.

Claim 16 narrows further to purified 50:50 DL PLG 4A. “DL” indicates a racemic lactide configuration, while the “4A” designation appears to identify a particular polymer grade or material specification used in the patented formulation.

A competing product using a different lactide:glycolide ratio, polymer molecular-weight specification or polymer grade could avoid claims 13, 14 or 16 while potentially remaining exposed to broader claims 1, 11, 12 or 15.

What is the importance of the pore-volume limitation?

The pore-volume limitation is one of the patent’s most important technical restrictions.

A total pore volume of about 0.1 mL/g or less indicates a relatively dense microsphere or polymer matrix. Lower porosity can reduce water penetration and limit rapid diffusion of exendin-4 from the particles. The claimed result is a lower initial burst and a flatter serum concentration curve.

The claim specifies mercury intrusion porosimetry as the measurement method. That creates several potential dispute points:

Sample preparation and drying conditions.
Instrument calibration.
Pressure range used for intrusion.
Whether pores outside the measurable range are included.
Treatment of interparticle voids.
Whether the test measures the finished product or an intermediate.

An accused formulation may challenge infringement through testing methodology, although the patent holder may argue that the claim requires the result, not a particular manufacturing process.

How does the Cmax/Cave limitation affect infringement?

The Cmax/Cave ratio is a pharmacokinetic limitation. It requires the maximum serum concentration during the release period to be approximately three times or less than the average serum concentration.

This limitation is significant because it can exclude formulations with a pronounced initial burst even if they use the same PLG polymer and exendin-4. A product may therefore match the composition but fall outside the claim based on its clinical or animal pharmacokinetic profile.

Key variables include:

Dose and route of administration.
Sampling interval.
Duration used to calculate Cave.
Patient population.
Assay methodology.
Whether the release period is one week or another period.
Variability among subjects.

Claims 17-20 add an approximately one-week release period. These claims are narrower than claim 1 because the claimed pharmacokinetic result must occur over the specified period.

Which claims are most relevant to Bydureon-type products?

The most commercially relevant claims are 15, 16, 18, 19 and 20.

Claim	Commercial relevance to extended-release exenatide
15	Exendin-4 at least about 5% w/w, sucrose at least about 2% w/w, biodegradable polymer and low pore volume
16	Purified 50:50 DL PLG 4A, exendin-4, sucrose, no ammonium sulfate, human diabetes treatment
18	Claim 15 plus approximately one-week release
19	Claim 16 plus approximately one-week release
20	Claim 17 plus exendin-4

The narrowest claim, claim 16, has several cumulative limitations. A product that does not use purified 50:50 DL PLG 4A, contains ammonium sulfate, or falls outside the stated exendin-4 and sucrose concentrations may avoid that claim. It could still face broader claim exposure if it satisfies claim 1 or claim 15.

When did US Patent 7,563,871 lose exclusivity?

The patent was issued on July 21, 2009. Its priority chain reaches back to the early 2000s, and the ordinary US patent term therefore ran into the 2020s rather than the 2030s [1].

The patent’s nominal term should be evaluated from the earliest effective nonprovisional filing date, subject to:

Patent term adjustment.
Any patent term extension.
Terminal disclaimers.
Maintenance-fee status.
Reexamination or post-grant changes.
Continuation or divisional patent rights.

The original patent is no longer a durable forward-looking exclusivity asset. Any current commercial barrier must be analyzed through later family members, Orange Book-listed patents and product-specific regulatory exclusivity.

What is the Orange Book status of US 7,563,871?

The Orange Book determines whether a patent is formally listed for an approved drug product and whether an applicant must certify against that patent in an abbreviated application [3].

US 7,563,871 is associated with the exendin-4 extended-release formulation field, but patent-number association with Bydureon development is not equivalent to a current Orange Book listing. A listing must be checked against the relevant product entry, including the specific Bydureon or Bydureon BCise product and the active patent listing at the time of an ANDA or 505(b)(2) filing.

For an applicant, the relevant questions are:

Is the patent currently listed against the reference product?
Is the listed patent identified as a formulation, method-of-use or drug-substance patent?
Has the patent expired or been delisted?
Does the applicant need a Paragraph IV certification?
Is a section viii statement available for any method-of-use listing?

The patent’s expiration history materially reduces the likelihood that it remains the principal current Orange Book obstacle.

Are there Paragraph IV challenges or settlements?

The claims supplied do not establish the existence, timing or outcome of a Paragraph IV challenge, ANDA litigation or settlement agreement.

For extended-release exenatide, the competitive filing risk is more complex than for a conventional immediate-release tablet. A follow-on applicant must address:

Equivalence of the exendin-4 active ingredient.
Microsphere composition and particle characteristics.
Release profile.
Injection-site tolerability.
Device performance.
Sterility and manufacturing controls.
Clinical bridging under the selected FDA pathway.

A Paragraph IV challenge to an unexpired listed formulation patent could trigger a Hatch-Waxman suit and a potential 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii). If the patent is expired or no longer listed, the certification risk changes substantially [3], [4].

No settlement terms should be inferred from the patent claims. A settlement would require separate litigation or regulatory records.

How strong is the patent estate?

Strengths

The patent has several technical features that can be effective against closely matched microsphere products:

It covers the combination of polymer, peptide and sugar.
It includes an objective pore-volume threshold.
It claims a pharmacokinetic profile.
It separately targets exendin-4.
It covers one-week release.
Claim 16 adds a specific PLG grade and excludes ammonium sulfate.

The combination of formulation and performance limitations can make simple design-around analysis difficult where a competitor seeks to reproduce the same product characteristics.

Weaknesses

The estate has important limitations:

The core patent term is substantially consumed or expired.
Several claims rely on “about,” creating numerical boundary disputes.
Pore volume depends on test conditions.
Cmax/Cave depends on study design and pharmacokinetic calculations.
Claims 15 and 16 are narrow and require multiple cumulative elements.
A competitor may change polymer ratio, polymer grade, excipient system or release duration.
The patent does not broadly cover every long-acting peptide formulation.

The strongest historical position was against a close copy of a once-weekly exendin-4 PLG microsphere formulation. Its present value is primarily historical, evidentiary and relevant to patent-family analysis.

What generic entry risks exist for exenatide extended release?

A generic or follow-on product would likely face four separate risk categories.

Formulation risk

The applicant must avoid reproducing the claimed combination of exendin-4, PLG, sugar, low pore volume and low Cmax/Cave ratio if any enforceable family patent remains relevant.

Manufacturing risk

Manufacturing conditions affect particle size, porosity, encapsulation efficiency and release kinetics. The manufacturing process may be protected by later patents even if US 7,563,871 is expired.

Regulatory risk

The FDA may require a complex demonstration of pharmaceutical equivalence and comparable release behavior. Bydureon is an injectable extended-release microsphere product, not a simple immediate-release peptide injection [2].

Device risk

Pre-filled pens, suspension systems, reconstitution components and injection devices may have separate patents or regulatory requirements. A formulation design-around does not automatically create a substitutable commercial product.

How does this patent compare with competing GLP-1 patent estates?

US 7,563,871 is materially different from the patent estates for liraglutide, semaglutide and tirzepatide.

Product class	Principal protection focus
Exendin-4 extended release	PLG microspheres, excipients, porosity and weekly pharmacokinetics
Liraglutide	Modified peptide sequence, acylation and formulation
Semaglutide	Modified peptide, acyl chain, formulations, dosing and manufacturing
Tirzepatide	Dual GIP/GLP-1 peptide sequence, formulations and methods of treatment
Insulin analogs	Protein sequence, formulation, devices and dosing regimens

The 7,563,871 patent is a delivery-system patent. It does not protect the broad GLP-1 mechanism or all GLP-1 receptor agonists. A competing peptide can operate outside its scope even if it has the same therapeutic objective.

What licensing and ownership issues affect the patent?

The development of extended-release exenatide involved collaboration and licensing relationships around the active peptide, biodegradable microsphere technology and commercial product development. Amylin Pharmaceuticals was the principal developer of Bydureon, while Alkermes supplied or contributed long-acting microsphere technology. AstraZeneca later acquired Amylin and assumed the relevant commercial rights.

Patent ownership, exclusive licensing and product commercialization rights should be separated:

The patent assignee may not be the current commercial product owner.
A licensee may hold enforcement or commercialization rights.
Technology suppliers may own parallel process patents.
Later patents may belong to a different corporate entity after acquisition or assignment.

The patent record alone does not establish the complete contractual licensing chain.

Key Takeaways

US 7,563,871 covers sustained-release biodegradable polymer compositions containing a biologically active polypeptide and sugar.
The core technical limits are total pore volume of about 0.1 mL/g or less and a Cmax/Cave ratio of about 3 or less.
Claims 15 and 16 are the main exendin-4 commercial claims.
Claim 16 is particularly narrow because it requires purified 50:50 DL PLG 4A, exendin-4, sucrose, no ammonium sulfate and suitability for treating diabetes.
Claims 17-20 focus on approximately one-week release and exendin-4.
The patent’s original term was tied to early-2000s priority filings and is not a durable current exclusivity asset.
Current entry risk depends on later formulation, process, device and Orange Book-listed patents.
The patent does not cover all GLP-1 agonists or all sustained-release peptide products.
A close copy of the Bydureon-type PLG microsphere system would historically have presented the greatest infringement exposure.
Pore-volume testing and pharmacokinetic study design would be central to any infringement dispute.

FAQs

Does US 7,563,871 cover immediate-release exenatide?

No. The claims require a sustained-release composition and, in several claims, an approximately one-week release period.

Does the patent cover semaglutide or tirzepatide?

Not as such. The broad polypeptide language could theoretically encompass certain peptide compositions, but the product would still need to satisfy every polymer, sugar, pore-volume and pharmacokinetic limitation.

Can a formulation avoid the patent by removing sucrose?

Removing sucrose would generally avoid the express sugar limitation in claim 1 and related claims, but a different patent could protect the replacement excipient or formulation.

Is claim 16 broader than claim 15?

No. Claim 16 is narrower. It adds purified 50:50 DL PLG 4A, absence of ammonium sulfate, human diabetes treatment and the specific composition context.

Does expiration of US 7,563,871 eliminate all Bydureon patent risk?

No. Expiration of this patent does not eliminate later patents covering manufacturing, microsphere processing, formulations, devices, reconstitution or methods of treatment.

References

United States Patent and Trademark Office. (2009). US Patent No. 7,563,871, Sustained release compositions.
U.S. Food and Drug Administration. (2021). BYDUREON BCISE (exenatide extended-release) injection prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
21 U.S.C. § 355(j). Abbreviated applications for new drugs and patent certifications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1734971	⤷ Start Trial	16/2012	Austria	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	122012000028	Germany	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	C300526	Netherlands	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	CA 2012 00015	Denmark	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	PA2012006	Lithuania	⤷ Start Trial
European Patent Office	1734971	⤷ Start Trial	91989	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,563,871

Summary for Patent: 7,563,871